Restricted accessResearch articleFirst published online 2010-03
Mesenchymal Stromal Cells,Colony-Forming Unit Fibroblasts,From Bone Marrow of Untreated Advanced Breast and Lung Cancer Patients Suppress Fibroblast Colony Formation From Healthy Marrow
We have shown that bone marrow (BM) from untreated advanced lung and breast cancer patients (LCP and BCP) have a reduced number of colony-forming unit fibroblasts (CFU-Fs) or mesenchymal stem cells (MSCs). Factors that regulate the proliferation and differentiation of CFU-F are produced by the patients’ BM microenvironment. We have now examined whether conditioned media (CM) from patients’ CFU-F-derived stromal cells also inhibits the colony-forming efficiency (CFE) of CFU-F in primary cultures from healthy volunteers (HV)-BM. Thus the number and proliferation potential of HV-CFU-F were also found to be decreased and similar to colony numbers and colony size of patients’ CFU-F. Stromal cells from both of these types of colonies appeared relatively larger and lacked the characteristic spindle morphology typically seen in healthy stromal cells. We developed an arbitrary mesenchymal stromal cell maturational index by taking three measures consisting of stromal cell surface area, longitudinal and horizontal axis. All stromal indices derived from HV-CFU-F grown in patients’ CM were similar to those from stromal elements derived from patients’ CFU-F. These indices were markedly higher than stromal indices typical of HV-CFU-F cultured in healthy CM or standard medium [α-medium plus 20% heat-inactivated fetal bovine serum (FBS)]. Patients’ CM had increased concentrations of the CFU-F inhibitor, GM-CSF, and low levels of bFGF and Dkk-1, strong promoters of self-renewal of MSCs, compared to the levels quantified in CM from HV-CFU-F. Moreover, the majority of patients’ MSCs were unresponsive in standard medium and healthy CM to give CFU-F, indicating that the majority of mesenchymal stromal cells from patients’ CFU-F are locked in maturational arrest. These results show that alterations of GM-CSF, bFGF, and Dkk-1 are associated with deficient cloning and maturation arrest of CFU-F. Defective autocrine and paracrine mechanisms may be involved in the BM microenvironments of LCP and BCP.
Get full access to this article
View all access options for this article.
References
1.
EavesCJ, CashmanJD and EavesAC. (1991). Methodology of long-term culture of human hematopoietic cells. J Tissue Culture Methods, 13:55–62.
2.
Janowska-WieczorekA, MajkaM, RatajczakJ and RatajczakMZ. (2002). Autocrine/paracrine mechanisms in human hematopoiesis. Stem Cells, 19:99–107.
3.
GregoryCA, YlostaloJ and ProckopDJ. (2005). Adult bone marrow stem/progenitor cells (MSCs) are preconditioned by microenvironmental “niches” in culture: a two-stage hypothesis for regulation of MSC fate. Sci STKE, 294:pe 37.
4.
ChenXD, DusevichV, FengJQ, ManolagasSC and JilkaRL. (2007). Extracellular matrix made by bone marrow cells facilitates expansion of marrow-derived mesenchymal progenitor cells and prevents their differentiation into osteoblasts. J Bone Miner Res, 22:1943–1956.
5.
DexterTM, AllenTD and LajthaLG. (1976). Conditions controlling the proliferation of hematopoietic stem cells in-vitro. J Cell Physiol, 91:335–344.
6.
FernándezM and MinguellJJ. (1984). The role of collagen in hematopoiesis: an interpretative review. Exp Hematol, 12:139–146.
7.
GronthosS, ZannettinoAC, HaySJ, ShiS, GravesSE, KortesidisA and SimmonsPJ. (2003). Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci, 116:1827–1835.
8.
BiancoP, RiminucciM, GronthosS and Gehron RobeyP. (2001). Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells, 19:180–192.
9.
TocciA and ForteL. (2003). Mesenchymal stem cell: use and perspectives. Hematol J, 4:92–96.
RahamanMN and MaoJJ. (2005). Stem cell–based composite tissue constructs for regenerative Medicine. Biotechnol Bioeng, 20:1–24.
12.
PountosI and GiannoudisPV. (2005). Biology of mesenchymal stem cells. Injury, 36S:8–12.
13.
ColterDC, ClassR, DiGirolamoCM and ProckopDJ. (2000). Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci USA, 97:3213–3218.
14.
DiGirolamoCM, StokesD, ColterD, PhinneyDG, ClassR and ProckopDJ. (1999). Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol, 107:275–281.
15.
BakshD, SongL and TuanRS. (2004). Adult mesenchymal stem cells: characterization and application in cell and gene therapy. J Cell Mol Med, 8:301–316.
16.
GordonMY. (1994). Physiology and function of the haematopoietic microenvironment. Br J Haematol, 86:241–242.
17.
BonyadiM, WaldmanSD, LiuD, AubinJE, GrynpasMD and StanfordWL. (2003). Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice. Proc Natl Acad Sci USA, 100:5840–5845.
18.
CompstonJE. (2002). Bone marrow and bone: a functional unit. J Endocrinol, 173:387–394.
19.
BenBaruch A. (2003). Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res, 5:31–36.
20.
HoneggerAE, HoferEL, RIBarañao, MackinlayTA, MackinlayDA, BullorskyEO, BordenaveRH and ChasseingNA. (2002). Interleukin-1 beta, transforming growth factor beta 1, prostaglandin E2, and fibronectin levels in the conditioned mediums of bone marrow fibroblast cultures from lung and breast cancer patients. Ann Hematol, 81:80–85.
21.
ChasseingNA, HoferE, BordenaveRH, ShanleyC and RumiLS. (2001). Bone marrow fibroblasts in patients with advanced lung cancer. Braz J Med Biol Res, 34:1457–1463.
22.
ChasseingNA, TrejoYG, BordenaveRH, BullorskyEO, DiazNB and RumiLS. (1997). Bone marrow fibroblastic progenitors in patients with advanced breast cancer. Breast Cancer Res Treat, 45:211–218.
23.
ChasseingNA, BordenaveRH, BullorskyEO, DiazNB, StemmelinGR and RumiLS. (1997). Fibroblastic colony-forming units and levels of tumor necrosis factor and prostaglandin E2 in bone marrow cultures from patients with advanced lung carcinoma. Cancer, 80:1914–1919.
24.
Castro-MalaspinaH, GayRE, ResnickG, KapoorN, MeyersP, ChiarieriD, McKenzieS, BroxmeyerHE and MooreMA. (1980). Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood, 56:289–301.
25.
KollerMR, MaherRJ, ManchelI, OxenderM and SmithAK. (1998). Alternatives to animal sera for human bone marrow cell expansion: human serum and serum-free media. J Hematother, 7:413–423.
26.
Castro-MalaspinaH. (1984). Myelofibrosis and the biology of connective tissue. In: Progress in clinical and Biological Research, vol. 154. BerckPD, Castro MalaspinaH, WassermanLR, eds. Alan R. Liss Inc, New York.
27.
NeuhuberB, SwangerSA, HowardL, MackayA and FischerI. (2008). Effects of plating density and culture time on bone marrow stromal cell characteristics. Exp Hematol, 36:1176–1185.
28.
SekiyaI, LarsonBL, SmithJR, PochampallyR, CuiJG and ProckopDJ. (2002). Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells, 20: 530–541.
29.
ScuttA and BertramP. (1999). Basic fibroblast growth factor in the presence of dexamethasone stimulates colony formation, expansion, and osteoblastic differentiation by rat bone marrow stromal cells. Calcif Tissue Int, 64:69–77.
30.
ImaizumiT, Jean-LouisF, DubertretML, BaillyC, CicurelL, Petchot-BacqueJP and DubertretL. (1996). Effect of human basic fibroblast growth factor on fibroblast proliferation, cell volume, collagen lattice contraction: in comparison with acidic type. J Dermatol Sci, 11:134–141.
31.
ProckopDJ, GregoryCA and SpeesJL. (2003). One strategy for cell and gene therapy: Harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci USA, 100:11917–11923.
32.
HoferEL, AHernaldo Insúa, Fernández ValloneV, FeldmanL, BordenaveRH and ChasseingNA. (2007). Plasticity of mesenchymal stem cell from bone marrow of patients with lung and breast cancer. Biocell (Argentina), 31,(2):abstract 7, p. 327.
33.
FernandezM and MinguellJJ. (1996). Adhesive interactions in the hematopoietic system: regulation by cytokines. Proc Soc Exp Biol Med, 212:313–323.
34.
XuYX, LuHB and ZhangGS. (2000). Effects of rhGM-CSF and rhG-CSF on growth of CFU-F derived from acute leukemia (AL) patient bone marrow in vitro. Hunan Yi Ke Da Xue Xue Bao, 25:185–187.
35.
GregoryCA, SinghH, PerryAS and ProckopDJ. (2003). The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem, 278:28067–28078.
RougierF, DupuisF and DenizotY. (1996). Human bone marrow fibroblasts-an overview of their characterization, proliferation and inflammatory mediator production. Hematol Cell Ther, 38:241–246.
38.
KimuraA, KatohO and KuramotoA. (1988). Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor-beta on the growth of human marrow fibroblasts. Br J Haematol, 69:9–12.
39.
KuznetsovSA, FriedensteinAJ and RobeyPG. (1997). Factors required for bone marrow stromal fibroblast colony formation in-vitro. Br J Haematol, 97:561–570.
40.
KwonBS, WangS, UdagawaN, HaridasV, LeeZH, KimKK, OhKO, GreeneJ, LiY, SuJ, GentzR, AggarwalBB and NiJ. (1998). TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J, 12:845–854.
41.
WilkimsBS and JonesDB. (1996). Contribution of monocyte/macrophage differentiation to the stromal layer in human long-term bone marrow cultures. Biological, 24:313–318.
42.
KimuraA, KatohO, HyodoH, KusumiS and KuramotoA. (1991). Autocrine and/or paracrine mechanism operate during the growth of human bone marrow fibroblasts. Br J Haematol, 78:469–473.
TamamaK, FanVH, GriffithLG, BlairHC and WellsA. (2006). Epidermal growth factor as a candidate for ex-vivo expansion of bone marrow derived mesenchymal stem cells. Stem Cells, 24:686–695.
45.
NgF, BoucherS, KohS, SastryKS, ChaseL, LakshmipathyU, ChoongC, YangZ, VemuriMC, RaoMS and TanavdeV. (2008). PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood, 112:295–307.
46.
BryckaertMC, LindrothM, LonnA, TobelemG and WastesonA. (1988). Transforming growth factor (TGF beta) decreases the proliferation of human bone marrow fibroblasts by inhibiting the platelet-derived growth factor (PDGF) binding. Exp Cell Res, 179:311–321.
47.
FriedensteinAJ, LatzinikNV, GorskayaYF, LuriaEA and MoskvinaIL. (1999). Bone marrow stromal colony formation requires stimulation by haemopoietic cells. Bone Miner, 18:199–213.
48.
YamadaM, SuzuS, Tanaka-DouzonoM, WakimotoN, HatakeK, HayasawaH and MotoyoshiK. (2000). Effect of cytokines on the proliferation/differentiation of stroma-initiating cells. J Cell Physiol, 184:351–355.
49.
FromiguéO, ModrowskiD and MariePJ. (2004). Growth factors and bone formation in osteoporosis: roles for fibroblast growth factor and transforming growth factor beta. Curr Pharm Des, 10:2593–2603.
50.
HoferEL, LaRussaV, HoneggerAE, BullorskyEO, BordenaveRH and ChasseingNA. (2005). Alteration on the expression of IL-1, PDGF, TGF-beta, EGF, and FGF receptors and c-Fos and c-Myc proteins in bone marrow mesenchymal stroma cells from advanced untreated lung and breast cancer patients. Stem Cells Dev, 14:587–594.
